A bill to prohibit biometric surveillance by the Federal Government without explicit statutory authorization and to withhold certain Federal public safety grants from State and local governments that engage in biometric surveillance.

On September 24, 2026, Senator Edward J. Markey (D-MA) introduced S5544, a bill to prohibit biometric surveillance by the Federal Government without explicit statutory authorization and to withhold certain Federal public safety grants from State and local governments that engage in biometric surveillance. The bill was read twice and referred to the Committee on the Judiciary, marking its first legislative step. It has three original cosponsors: Senators Merkley, Wyden, and Warren, all Democrats.

The bill does not authorize any funding; its primary mechanism is a prohibition on federal agencies using biometric surveillance unless Congress specifically authorizes it, and a penalty for state/local governments that use such surveillance in the form of withheld federal public safety grants. This is a regulatory restriction rather than a spending bill, so there is no direct appropriation or authorization of funds.

No convergence data was provided, so this bill stands alone as an isolated legislative signal. The legislative path forward is uncertain: it must clear the Judiciary Committee, pass the Senate, and then the House, all of which face significant political hurdles given the partisan sponsorship and the current composition of Congress.

Structural winners and losers: The bill is bearish for companies that supply biometric surveillance systems to government entities, as it would reduce demand from federal agencies and create a financial disincentive for state/local adoption. However, no publicly traded US companies derive a material portion of revenue from government biometric surveillance contracts, and the bill is too early-stage to warrant specific ticker-level impact. The timeline for any market effect is distant, requiring passage and implementation.

Given the early stage, low sponsor seniority on the relevant committee, and lack of companion legislation, the probability of enactment in this Congress is low. Investors should monitor for committee action but not adjust positions based on this introduction alone.